SCHEMBL20844355

SCHEMBL20844355

CCN(Cc1ccccc1)c1nc(N)nc(N)n1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.63
TSHR P16473 1/20 0.56
CNR2 P34972 1/20 0.47
CRHR1 P34998 2/20 0.47
NOS1 P29475 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
TP53 P04637 1/20 0.43
AOC3 Q16853 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPC1 O15118 1/20 0.41
JAK2 O60674 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11292840 0.91 MAPT (0.50) MAPTTSHRNOS1SMN1; SMN2AOC3
SCHEMBL8059710 0.80 NOS1 (0.42) MAPTTSHRNOS1SMN1; SMN2AOC3
SCHEMBL14869399 0.80 SMN1; SMN2 (0.58) MAPTTSHRSMN1; SMN2AOC3RAB9A
SCHEMBL2339204 0.78 MAPT (0.60) MAPTTSHRSMN1; SMN2
SCHEMBL12609970 0.77 TSHR (0.64) MAPTTSHRCNR2CRHR1SMN1; SMN2
SCHEMBL2726098 0.77 SMN1; SMN2 (0.48) MAPTTSHRCNR2CRHR1SMN1; SMN2
SCHEMBL7754258 0.76 NPSR1 (0.57) SMN1; SMN2
SCHEMBL2338559 0.74 MAPT (0.66) MAPTTSHRSMN1; SMN2RAB9A
SCHEMBL10807532 0.73 TSHR (0.75) MAPTTSHRCNR2CYP2C19NPC1
SCHEMBL179996 0.72 TSHR (1.00) MAPTTSHRCNR2PDE4DCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10640475-B2 Compositions and methods to produce alkoxylated triazine-arlhydroxy-aldehyde condensates HEXION INC. (US) 2020-05-05 US disclosed
US-10604614-B2 Compositions and methods to produce alkoxylated triazine-arylhydroxy-aldehyde condensates HEXION INC. (US) 2020-03-31 US disclosed
US-20190092736-A1 NOVEL COMPOSITIONS AND METHODS TO PRODUCE ALKOXYLATED TRIAZINE-ARLHYDROXY-ALDEHYDE CONDENSATES JPMORGAN CHASE BANK, N.A. 2019-03-28 US disclosed
US-20190092894-A1 NOVEL COMPOSITIONS AND METHODS TO PRODUCE ALKOXYLATED TRIAZINE-ARYLHYDROXY-ALDEHYDE CONDENSATES JPMORGAN CHASE BANK, N.A. 2019-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10640475-B2 Compositions and methods to produce alkoxylated triazine-arlhydroxy-aldehyde condensates ALKBH3, AHR, AKR7A2 MAPT 2972/4885TSHR 3675/4885CNR2 1093/4885
US-20190092736-A1 NOVEL COMPOSITIONS AND METHODS TO PRODUCE ALKOXYLATED TRIAZINE-ARLHYDROXY-ALDEHYDE CONDENSATES ALKBH3, ALKBH5, ALKBH2 MAPT 3262/4885TSHR 3812/4885CNR2 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.